{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T13:04:51Z","timestamp":1788267891521,"version":"build-2803163510"},"reference-count":68,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T00:00:00Z","timestamp":1769472000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T00:00:00Z","timestamp":1769472000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"the Youth Project of \u201cGusu healthy\u201d","award":["GSWS2022110"],"award-info":[{"award-number":["GSWS2022110"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Genes Genom"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1007\/s13258-026-01737-z","type":"journal-article","created":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T12:31:51Z","timestamp":1769517111000},"page":"533-548","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Epitranscriptomic regulation of NVP-BEZ235 resistance in ccRCC via the YTHDF3-SYNM regulatory pathway"],"prefix":"10.1007","volume":"48","author":[{"given":"Ruiang","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheng","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erchang","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xi","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinchi","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyang","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tian","family":"Rao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaohan","family":"Ren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiyang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chen","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoxiang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,27]]},"reference":[{"issue":"11","key":"1737_CR1","doi-asserted-by":"publisher","first-page":"4781","DOI":"10.21873\/anticanres.16675","volume":"43","author":"H Aweys","year":"2023","unstructured":"Aweys H, Lewis D, Sheriff M, Rabbani RD, Lapitan P, Sanchez E et al (2023) Renal Cell Cancer - insights in drug resistance mechanisms. Anticancer Res 43(11):4781\u20134792","journal-title":"Anticancer Res"},{"issue":"1","key":"1737_CR2","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1186\/s12958-025-01427-7","volume":"23","author":"J Bindels","year":"2025","unstructured":"Bindels J, Bernet L, Squatrito M, Nisolle M, Munaut C (2025) BEZ235-mediated PI3K\/mTOR dual inhibition improves ovarian follicle survival in a preclinical model. Reprod Biol Endocrinol 23(1):91","journal-title":"Reprod Biol Endocrinol"},{"key":"1737_CR3","unstructured":"Global Burden of Disease Cancer C, Fitzmaurice C, Dicker D, Pain A, Hamavid H, Moradi-Lakeh M, et al (2015) The Global Burden of Cancer 2013. JAMA Oncol 1(4):505\u2013527"},{"issue":"4","key":"1737_CR4","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1002\/2211-5463.12806","volume":"10","author":"J Cai","year":"2020","unstructured":"Cai J, Xia J, Zou J, Wang Q, Ma Q, Sun R et al (2020) The PI3K\/mTOR dual inhibitor NVP-BEZ235 stimulates mutant p53 degradation to exert anti-tumor effects on triple-negative breast cancer cells. FEBS Open Bio 10(4):535\u2013545","journal-title":"FEBS Open Bio"},{"issue":"8","key":"1737_CR5","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.1038\/sj.bjc.6604995","volume":"100","author":"P Cao","year":"2009","unstructured":"Cao P, Maira SM, Garcia-Echeverria C, Hedley DW (2009) Activity of a novel, dual PI3-kinase\/mTor inhibitor NVP-BEZ235 against primary human pancreatic cancers grown as orthotopic xenografts. Br J Cancer 100(8):1267\u20131276","journal-title":"Br J Cancer"},{"issue":"6","key":"1737_CR6","first-page":"893","volume":"55","author":"Z Cao","year":"2023","unstructured":"Cao Z, An L, Han Y, Jiao S, Zhou Z (2023) The Hippo signaling pathway in gastric cancer. Acta Biochim Biophys Sin 55(6):893","journal-title":"Acta Biochim Biophys Sin"},{"issue":"7","key":"1737_CR7","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1634\/theoncologist.2016-0145","volume":"21","author":"MI Carlo","year":"2016","unstructured":"Carlo MI, Molina AM, Lakhman Y, Patil S, Woo K, DeLuca J et al (2016) A Phase Ib Study of BEZ235, a Dual Inhibitor of Phosphatidylinositol 3-Kinase (PI3K) and Mammalian Target of Rapamycin (mTOR), in Patients With Advanced Renal Cell Carcinoma. Oncologist 21(7):787\u2013788","journal-title":"Oncologist"},{"issue":"9","key":"1737_CR8","first-page":"3065","volume":"118","author":"A Carracedo","year":"2008","unstructured":"Carracedo A, Ma L, Teruya-Feldstein J, Rojo F, Salmena L, Alimonti A et al (2008) Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer. J Clin Invest 118(9):3065\u20133074","journal-title":"J Clin Invest"},{"issue":"20","key":"1737_CR9","doi-asserted-by":"publisher","first-page":"8361","DOI":"10.1158\/0008-5472.CAN-08-0878","volume":"68","author":"R Chaisuparat","year":"2008","unstructured":"Chaisuparat R, Hu J, Jham BC, Knight ZA, Shokat KM, Montaner S (2008) Dual inhibition of PI3Kalpha and mTOR as an alternative treatment for Kaposi\u2019s sarcoma. Cancer Res 68(20):8361\u20138368","journal-title":"Cancer Res"},{"key":"1737_CR10","unstructured":"Cheng X-l, Li Z-d, Jiang B-Q, Zhuang Z-g, Zhuang C-j (2011) Interactions between the Sonic Hedgehog signaling pathway and the cAMP\/PKA signaling pathway in LKB1 transfected breast cancer cells. Fudan Univ J Med Sci"},{"issue":"3","key":"1737_CR11","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1002\/(SICI)1098-2264(199807)22:3<200::AID-GCC5>3.0.CO;2-#","volume":"22","author":"SC Clifford","year":"1998","unstructured":"Clifford SC, Prowse AH, Affara NA, Buys CH, Maher ER (1998) Inactivation of the von Hippel-Lindau (VHL) tumour suppressor gene and allelic losses at chromosome arm 3p in primary renal cell carcinoma: evidence for a VHL-independent pathway in clear cell renal tumourigenesis. Genes Chromosomes Cancer 22(3):200\u2013209","journal-title":"Genes Chromosomes Cancer"},{"issue":"8","key":"1737_CR12","doi-asserted-by":"publisher","first-page":"2588","DOI":"10.1111\/cas.16228","volume":"115","author":"C Dai","year":"2024","unstructured":"Dai C, Cao J, Tang Y, Jiang Y, Luo C, Zheng J (2024) <scp>YTHDF3<\/scp> phase separation regulates <scp>HSPA13<\/scp>\u2010dependent clear cell renal cell carcinoma development and immune evasion. Cancer Sci 115(8):2588\u20132601","journal-title":"Cancer Sci"},{"issue":"7397","key":"1737_CR13","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1038\/nature11112","volume":"485","author":"D Dominissini","year":"2012","unstructured":"Dominissini D, Moshitch-Moshkovitz S, Schwartz S, Salmon-Divon M, Ungar L, Osenberg S et al (2012) Topology of the human and mouse m6A RNA methylomes revealed by m6A-seq. Nature 485(7397):201\u2013206","journal-title":"Nature"},{"issue":"2","key":"1737_CR14","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0191890","volume":"13","author":"P Earwaker","year":"2018","unstructured":"Earwaker P, Anderson C, Willenbrock F, Harris AL, Protheroe AS, Macaulay VM (2018) RAPTOR up-regulation contributes to resistance of renal cancer cells to PI3K-mTOR inhibition. PLoS ONE 13(2):e0191890","journal-title":"PLoS ONE"},{"issue":"20 Pt 1","key":"1737_CR15","doi-asserted-by":"publisher","first-page":"5924","DOI":"10.1158\/1078-0432.CCR-06-1736","volume":"12","author":"M Evangelista","year":"2006","unstructured":"Evangelista M, Tian H, de Sauvage FJ (2006) The hedgehog signaling pathway in cancer. Clin Cancer Res 12(20 Pt 1):5924\u20135928","journal-title":"Clin Cancer Res"},{"issue":"6","key":"1737_CR16","doi-asserted-by":"publisher","first-page":"2395","DOI":"10.1016\/S0022-5347(05)64153-5","volume":"168","author":"I Frank","year":"2002","unstructured":"Frank I, Blute ML, Cheville JC, Lohse CM, Weaver AL, Zincke H (2002) An outcome prediction model for patients with clear cell renal cell carcinoma treated with radical nephrectomy based on tumor stage, size, grade and necrosis: the SSIGN score. J Urol 168(6):2395\u20132400","journal-title":"J Urol"},{"issue":"5","key":"1737_CR17","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1038\/nrg3724","volume":"15","author":"Y Fu","year":"2014","unstructured":"Fu Y, Dominissini D, Rechavi G, He C (2014) Gene expression regulation mediated through reversible m(6)A RNA methylation. Nat Rev Genet 15(5):293\u2013306","journal-title":"Nat Rev Genet"},{"issue":"11","key":"1737_CR18","doi-asserted-by":"publisher","first-page":"2812","DOI":"10.1158\/0008-5472.CAN-18-3592","volume":"79","author":"T Fukumoto","year":"2019","unstructured":"Fukumoto T, Zhu H, Nacarelli T, Karakashev S, Fatkhutdinov N, Wu S et al (2019) N(6)-methylation of adenosine of FZD10 mRNA contributes to PARP inhibitor resistance. Cancer Res 79(11):2812\u20132820","journal-title":"Cancer Res"},{"issue":"4","key":"1737_CR19","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1016\/j.cell.2013.10.026","volume":"155","author":"JM Fustin","year":"2013","unstructured":"Fustin JM, Doi M, Yamaguchi Y, Hida H, Nishimura S, Yoshida M et al (2013) RNA-methylation-dependent RNA processing controls the speed of the circadian clock. Cell 155(4):793\u2013806","journal-title":"Cell"},{"issue":"8","key":"1737_CR20","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.1038\/sj.bjc.6603024","volume":"94","author":"RM Glasspool","year":"2006","unstructured":"Glasspool RM, Teodoridis JM, Brown R (2006) Epigenetics as a mechanism driving polygenic clinical drug resistance. Br J Cancer 94(8):1087\u20131092","journal-title":"Br J Cancer"},{"key":"1737_CR21","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.578963","volume":"10","author":"PJ Gong","year":"2020","unstructured":"Gong PJ, Shao YC, Yang Y, Song WJ, He X, Zeng YF et al (2020) Analysis of N6-methyladenosine methyltransferase reveals METTL14 and ZC3H13 as tumor suppressor genes in breast cancer. Front Oncol 10:578963","journal-title":"Front Oncol"},{"issue":"9916","key":"1737_CR22","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1016\/S0140-6736(13)62226-6","volume":"383","author":"D Hanahan","year":"2014","unstructured":"Hanahan D (2014) Rethinking the war on cancer. Lancet 383(9916):558\u2013563","journal-title":"Lancet"},{"issue":"9","key":"1737_CR23","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1007\/s12094-013-1151-9","volume":"16","author":"K Harada","year":"2014","unstructured":"Harada K, Miyake H, Kusuda Y, Fujisawa M (2014) Characterization of mechanism involved in acquired resistance to sorafenib in a mouse renal cell cancer RenCa model. Clin Transl Oncol 16(9):801\u2013806","journal-title":"Clin Transl Oncol"},{"issue":"1","key":"1737_CR24","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1093\/abbs\/gmu106","volume":"47","author":"L Hong","year":"2015","unstructured":"Hong L, Cai Y, Jiang M, Zhou D, Chen L (2015) The hippo signaling pathway in liver regeneration and tumorigenesis. Acta Biochim Biophys Sin 47(1):46\u201352","journal-title":"Acta Biochim Biophys Sin"},{"issue":"10","key":"1737_CR25","doi-asserted-by":"publisher","first-page":"2671","DOI":"10.1002\/cncr.23896","volume":"113","author":"DA Kunkle","year":"2008","unstructured":"Kunkle DA, Uzzo RG (2008) Cryoablation or radiofrequency ablation of the small renal mass\u202f: a meta-analysis. Cancer 113(10):2671\u20132680","journal-title":"Cancer"},{"issue":"5112","key":"1737_CR26","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1126\/science.8493574","volume":"260","author":"F Latif","year":"1993","unstructured":"Latif F, Tory K, Gnarra J, Yao M, Duh FM, Orcutt ML et al (1993) Identification of the von Hippel-Lindau disease tumor suppressor gene. Science 260(5112):1317\u20131320","journal-title":"Science"},{"issue":"4","key":"1737_CR27","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1016\/j.biocel.2008.09.024","volume":"41","author":"WM Linehan","year":"2009","unstructured":"Linehan WM, Rubin JS, Bottaro DP (2009) VHL loss of function and its impact on oncogenic signaling networks in clear cell renal cell carcinoma. Int J Biochem Cell Biol 41(4):753\u2013756","journal-title":"Int J Biochem Cell Biol"},{"issue":"8","key":"1737_CR28","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1517\/14728222.2010.499361","volume":"14","author":"AM Liu","year":"2010","unstructured":"Liu AM, Xu MZ, Chen J, Poon RT, Luk JM (2010) Targeting YAP and hippo signaling pathway in liver cancer. Expert Opin Ther Targets 14(8):855\u2013868","journal-title":"Expert Opin Ther Targets"},{"issue":"5","key":"1737_CR29","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1016\/j.eururo.2015.01.005","volume":"67","author":"B Ljungberg","year":"2015","unstructured":"Ljungberg B, Bensalah K, Canfield S, Dabestani S, Hofmann F, Hora M et al (2015) EAU guidelines on renal cell carcinoma: 2014 update. Eur Urol 67(5):913\u2013924","journal-title":"Eur Urol"},{"issue":"4","key":"1737_CR30","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1016\/j.eururo.2022.03.006","volume":"82","author":"B Ljungberg","year":"2022","unstructured":"Ljungberg B, Albiges L, Abu-Ghanem Y, Bedke J, Capitanio U, Dabestani S et al (2022) European association of urology guidelines on renal cell carcinoma: the 2022 update. Eur Urol 82(4):399\u2013410","journal-title":"Eur Urol"},{"issue":"9","key":"1737_CR31","doi-asserted-by":"publisher","first-page":"1607","DOI":"10.1111\/febs.13614","volume":"283","author":"A Maity","year":"2016","unstructured":"Maity A, Das B (2016) N6-methyladenosine modification in mRNA: machinery, function and implications for health and diseases. FEBS J 283(9):1607\u20131630","journal-title":"FEBS J"},{"issue":"4","key":"1737_CR32","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1161\/CIRCULATIONAHA.118.033794","volume":"139","author":"P Mathiyalagan","year":"2019","unstructured":"Mathiyalagan P, Adamiak M, Mayourian J, Sassi Y, Liang Y, Agarwal N et al (2019) FTO-dependent N(6)-methyladenosine regulates cardiac function during remodeling and repair. Circulation 139(4):518\u2013532","journal-title":"Circulation"},{"key":"1737_CR33","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2013.31.15","author":"L Maute","year":"2013","unstructured":"Maute L, Wicht J, Zoernig M, Niederhagen M, Bergmann L (2013) Effect of the combination of the dual mTOR\/pI3K inhibitor NVP-BEZ235 with gemcitabine on growth inhibition in pancreatic cancer cells in vitro and in vivo. J Clin Oncol. https:\/\/doi.org\/10.1200\/jco.2013.31.15","journal-title":"J Clin Oncol"},{"issue":"2","key":"1737_CR34","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1016\/j.eururo.2012.04.049","volume":"62","author":"M Meskawi","year":"2012","unstructured":"Meskawi M, Sun M, Trinh QD, Bianchi M, Hansen J, Tian Z et al (2012) A review of integrated staging systems for renal cell carcinoma. Eur Urol 62(2):303\u2013314","journal-title":"Eur Urol"},{"issue":"6","key":"1737_CR35","doi-asserted-by":"publisher","first-page":"740","DOI":"10.21873\/cgp.20356","volume":"19","author":"K Mizutani","year":"2022","unstructured":"Mizutani K, Yokoi S, Sawada S, Sakamoto I, Kameyama K, Kamei S et al (2022) Derivative Chromosome 3 Loss from t(3;6)(q12;q14) Followed by DifferentialVHLMutations Underlie Multifocal ccRCC. Cancer Genomics - Proteomics 19(6):740\u2013746","journal-title":"Cancer Genomics - Proteomics"},{"key":"1737_CR36","doi-asserted-by":"publisher","DOI":"10.1038\/s41420-024-01972-x","author":"C Pan","year":"2024","unstructured":"Pan C, Hao X, Deng X, Lu F, Liu J, Hou W et al (2024) The roles of Hippo\/YAP signaling pathway in physical therapy. Cell Death Discov. https:\/\/doi.org\/10.1038\/s41420-024-01972-x","journal-title":"Cell Death Discov"},{"issue":"2","key":"1737_CR37","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/j.tcb.2017.10.001","volume":"28","author":"DP Patil","year":"2018","unstructured":"Patil DP, Pickering BF, Jaffrey SR (2018) Reading m(6)A in the transcriptome: m(6)A-binding proteins. Trends Cell Biol 28(2):113\u2013127","journal-title":"Trends Cell Biol"},{"issue":"37","key":"1737_CR38","doi-asserted-by":"publisher","first-page":"60169","DOI":"10.18632\/oncotarget.11109","volume":"7","author":"J Piao","year":"2016","unstructured":"Piao J, Chen L, Quan T, Li L, Quan C, Piao Y et al (2016) Superior efficacy of co-treatment with the dual PI3K\/mTOR inhibitor BEZ235 and histone deacetylase inhibitor Trichostatin A against NSCLC. Oncotarget 7(37):60169\u201360180","journal-title":"Oncotarget"},{"issue":"3","key":"1737_CR39","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1016\/j.eururo.2015.02.001","volume":"68","author":"PM Pierorazio","year":"2015","unstructured":"Pierorazio PM, Johnson MH, Ball MW, Gorin MA, Trock BJ, Chang P et al (2015) Five-year analysis of a multi-institutional prospective clinical trial of delayed intervention and surveillance for small renal masses: the DISSRM registry. Eur Urol 68(3):408\u2013415","journal-title":"Eur Urol"},{"issue":"6","key":"1737_CR40","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1007\/s10528-020-09982-x","volume":"58","author":"J Qiao","year":"2020","unstructured":"Qiao J, Li M, Li N, Xu L, Huang G, Yu J (2020) TIAM1 upregulation confers NVP-BEZ235 resistance to breast cancer cells through FGFR\/STAT3 pathway. Biochem Genet 58(6):953\u2013965","journal-title":"Biochem Genet"},{"key":"1737_CR41","doi-asserted-by":"publisher","first-page":"5138","DOI":"10.2741\/3070","volume":"13","author":"KM Redmond","year":"2008","unstructured":"Redmond KM, Wilson TR, Johnston PG, Longley DB (2008) Resistance mechanisms to cancer chemotherapy. Front Biosci 13:5138\u20135154","journal-title":"Front Biosci"},{"issue":"9669","key":"1737_CR42","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1016\/S0140-6736(09)60229-4","volume":"373","author":"BI Rini","year":"2009","unstructured":"Rini BI, Campbell SC, Escudier B (2009) Renal cell carcinoma. Lancet 373(9669):1119\u20131132","journal-title":"Lancet"},{"key":"1737_CR43","doi-asserted-by":"publisher","DOI":"10.1186\/1476-4598-10-90","volume":"10","author":"D Roulin","year":"2011","unstructured":"Roulin D, Waselle L, Dormond-Meuwly A, Dufour M, Demartines N, Dormond O (2011) Targeting renal cell carcinoma with NVP-BEZ235, a dual PI3K\/mTOR inhibitor, in combination with sorafenib. Mol Cancer 10:90","journal-title":"Mol Cancer"},{"issue":"6","key":"1737_CR44","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1016\/j.tig.2016.03.006","volume":"32","author":"IA Roundtree","year":"2016","unstructured":"Roundtree IA, He C (2016) Nuclear m(6)A reader YTHDC1 regulates mRNA splicing. Trends Genet 32(6):320\u2013321","journal-title":"Trends Genet"},{"issue":"7","key":"1737_CR45","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.1016\/j.cell.2017.05.045","volume":"169","author":"IA Roundtree","year":"2017","unstructured":"Roundtree IA, Evans ME, Pan T, He C (2017) Dynamic RNA modifications in gene expression regulation. Cell 169(7):1187\u20131200","journal-title":"Cell"},{"issue":"2","key":"1737_CR46","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1016\/j.trecan.2018.01.001","volume":"4","author":"R Salgia","year":"2018","unstructured":"Salgia R, Kulkarni P (2018) The genetic\/non-genetic duality of drug \u201cresistance\u201d in cancer. Trends Cancer 4(2):110\u2013118","journal-title":"Trends Cancer"},{"issue":"19","key":"1737_CR47","doi-asserted-by":"publisher","first-page":"8022","DOI":"10.1158\/0008-5472.CAN-08-1385","volume":"68","author":"V Serra","year":"2008","unstructured":"Serra V, Markman B, Scaltriti M, Eichhorn PJ, Valero V, Guzman M et al (2008) NVP-BEZ235, a dual PI3K\/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations. Cancer Res 68(19):8022\u20138030","journal-title":"Cancer Res"},{"issue":"1","key":"1737_CR48","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.cell.2010.02.027","volume":"141","author":"SV Sharma","year":"2010","unstructured":"Sharma SV, Lee DY, Li B, Quinlan MP, Takahashi F, Maheswaran S et al (2010) A chromatin-mediated reversible drug-tolerant state in cancer cell subpopulations. Cell 141(1):69\u201380","journal-title":"Cell"},{"key":"1737_CR49","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2022.106523","volume":"186","author":"U Sharma","year":"2022","unstructured":"Sharma U, Tuli HS, Uttam V, Choudhary R, Sharma B, Sharma U et al (2022) Role of hedgehog and hippo signaling pathways in cancer: a special focus on non-coding RNAs. Pharmacol Res 186:106523","journal-title":"Pharmacol Res"},{"issue":"1","key":"1737_CR50","first-page":"12","volume":"74","author":"RL Siegel","year":"2024","unstructured":"Siegel RL, Giaquinto AN, Jemal A (2024) Cancer statistics, 2024. CA Cancer J Clin 74(1):12\u201349","journal-title":"CA Cancer J Clin"},{"issue":"21","key":"1737_CR51","doi-asserted-by":"publisher","first-page":"22078","DOI":"10.18632\/aging.104053","volume":"12","author":"Z Sun","year":"2020","unstructured":"Sun Z, Jing C, Xiao C, Li T, Wang Y (2020) Prognostic risk signature based on the expression of three m6A RNA methylation regulatory genes in kidney renal papillary cell carcinoma. Aging (Albany NY) 12(21):22078\u201322094","journal-title":"Aging (Albany NY)"},{"key":"1737_CR52","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-025-08045-6","author":"Y Tan","year":"2025","unstructured":"Tan Y, Zhou C, Bian S, Bian H, Ren Y, Walter W et al (2025) The RNA N6-methyladenosine methylome coordinates long non-coding RNAs to mediate cancer drug resistance by activating PI3K signaling. Cell Death Dis. https:\/\/doi.org\/10.1038\/s41419-025-08045-6","journal-title":"Cell Death Dis"},{"key":"1737_CR53","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.ceb.2016.07.005","volume":"43","author":"PR Tata","year":"2016","unstructured":"Tata PR, Rajagopal J (2016) Cellular plasticity: 1712 to the present day. Curr Opin Cell Biol 43:46\u201354","journal-title":"Curr Opin Cell Biol"},{"issue":"2","key":"1737_CR54","first-page":"87","volume":"65","author":"LA Torre","year":"2015","unstructured":"Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A (2015) Global cancer statistics, 2012. CA Cancer J Clin 65(2):87\u2013108","journal-title":"CA Cancer J Clin"},{"issue":"11","key":"1737_CR55","doi-asserted-by":"publisher","first-page":"1369","DOI":"10.1038\/nm.4416","volume":"23","author":"LP Vu","year":"2017","unstructured":"Vu LP, Pickering BF, Cheng Y, Zaccara S, Nguyen D, Minuesa G et al (2017) The n(6)-methyladenosine (m(6)A)-forming enzyme METTL3 controls myeloid differentiation of normal hematopoietic and leukemia cells. Nat Med 23(11):1369\u20131376","journal-title":"Nat Med"},{"issue":"7481","key":"1737_CR56","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1038\/nature12730","volume":"505","author":"X Wang","year":"2014","unstructured":"Wang X, Lu Z, Gomez A, Hon GC, Yue Y, Han D et al (2014) N6-methyladenosine-dependent regulation of messenger RNA stability. Nature 505(7481):117\u2013120","journal-title":"Nature"},{"issue":"6","key":"1737_CR57","doi-asserted-by":"publisher","first-page":"1388","DOI":"10.1016\/j.cell.2015.05.014","volume":"161","author":"X Wang","year":"2015","unstructured":"Wang X, Zhao BS, Roundtree IA, Lu Z, Han D, Ma H et al (2015) N(6)-methyladenosine modulates messenger RNA translation efficiency. Cell 161(6):1388\u20131399","journal-title":"Cell"},{"key":"1737_CR58","doi-asserted-by":"publisher","first-page":"12845","DOI":"10.2147\/OTT.S283417","volume":"13","author":"JY Wang","year":"2020","unstructured":"Wang JY, Chen LJ, Qiang P (2020) The potential role of N6-methyladenosine (m6A) demethylase fat mass and obesity-associated gene (FTO) in human cancers. Onco Targets Ther 13:12845\u201312856","journal-title":"Onco Targets Ther"},{"issue":"7646","key":"1737_CR59","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1038\/nature21671","volume":"543","author":"Y Xiang","year":"2017","unstructured":"Xiang Y, Laurent B, Hsu CH, Nachtergaele S, Lu Z, Sheng W et al (2017) RNA m(6)A methylation regulates the ultraviolet-induced DNA damage response. Nature 543(7646):573\u2013576","journal-title":"Nature"},{"issue":"1","key":"1737_CR60","doi-asserted-by":"publisher","DOI":"10.1186\/s12935-020-01679-w","volume":"20","author":"S Xie","year":"2020","unstructured":"Xie S, Chen W, Chen K, Chang Y, Yang F, Lin A et al (2020) Emerging roles of RNA methylation in gastrointestinal cancers. Cancer Cell Int 20(1):585","journal-title":"Cancer Cell Int"},{"issue":"11","key":"1737_CR61","doi-asserted-by":"publisher","first-page":"1062","DOI":"10.1038\/s41422-018-0097-4","volume":"28","author":"F Yan","year":"2018","unstructured":"Yan F, Al-Kali A, Zhang Z, Liu J, Pang J, Zhao N et al (2018) A dynamic N(6)-methyladenosine methylome regulates intrinsic and acquired resistance to tyrosine kinase inhibitors. Cell Res 28(11):1062\u20131076","journal-title":"Cell Res"},{"issue":"3","key":"1737_CR62","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1210\/jc.2018-00619","volume":"104","author":"Y Yang","year":"2019","unstructured":"Yang Y, Shen F, Huang W, Qin S, Huang JT, Sergi C et al (2019) Glucose is involved in the dynamic regulation of m6A in patients with type 2 diabetes. J Clin Endocrinol Metab 104(3):665\u2013673","journal-title":"J Clin Endocrinol Metab"},{"issue":"8","key":"1737_CR63","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1038\/s41585-023-00851-x","volume":"21","author":"L Yang","year":"2024","unstructured":"Yang L, Ying J, Tao Q, Zhang Q (2024a) RNA n6-methyladenosine modifications in urological cancers: from mechanism to application. Nat Rev Urol 21(8):460\u2013476","journal-title":"Nat Rev Urol"},{"issue":"4","key":"1737_CR64","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1016\/j.ajur.2024.02.005","volume":"11","author":"Y Yang","year":"2024","unstructured":"Yang Y, Gan X, Zhang W, Zhu B, Huangfu Z, Shi X et al (2024b) Research progress of the hippo signaling pathway in renal cell carcinoma. Asian J Urol 11(4):511\u2013520","journal-title":"Asian J Urol"},{"key":"1737_CR65","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2025.1545952","author":"L Zhang","year":"2025","unstructured":"Zhang L, Zhang F, Liang H, Qin X, Mo Y, Chen S et al (2025) Hippo\/YAP signaling pathway in colorectal cancer: regulatory mechanisms and potential drug exploration. Front Oncol. https:\/\/doi.org\/10.3389\/fonc.2025.1545952","journal-title":"Front Oncol"},{"issue":"12","key":"1737_CR66","doi-asserted-by":"publisher","first-page":"1403","DOI":"10.1038\/cr.2014.151","volume":"24","author":"X Zhao","year":"2014","unstructured":"Zhao X, Yang Y, Sun BF, Shi Y, Yang X, Xiao W et al (2014) FTO-dependent demethylation of N6-methyladenosine regulates mRNA splicing and is required for adipogenesis. Cell Res 24(12):1403\u20131419","journal-title":"Cell Res"},{"issue":"4","key":"1737_CR67","doi-asserted-by":"publisher","first-page":"859","DOI":"10.3233\/CBM-170791","volume":"21","author":"X Zhao","year":"2018","unstructured":"Zhao X, Chen Y, Mao Q, Jiang X, Jiang W, Chen J et al (2018) Overexpression of YTHDF1 is associated with poor prognosis in patients with hepatocellular carcinoma. Cancer Biomark 21(4):859\u2013868","journal-title":"Cancer Biomark"},{"issue":"6","key":"1737_CR68","doi-asserted-by":"publisher","first-page":"326","DOI":"10.3892\/ol.2020.12189","volume":"20","author":"H Zhu","year":"2020","unstructured":"Zhu H, Shi Y, Jiao X, Yang G, Wang R, Yuan Y (2020) Synergistic antitumor effect of dual PI3K and mTOR inhibitor NVP-BEZ235 in combination with cisplatin on drug-resistant non-small cell lung cancer cell. Oncol Lett 20(6):326","journal-title":"Oncol Lett"}],"container-title":["Genes &amp; Genomics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13258-026-01737-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13258-026-01737-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13258-026-01737-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T10:03:41Z","timestamp":1777284221000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13258-026-01737-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,27]]},"references-count":68,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["1737"],"URL":"https:\/\/doi.org\/10.1007\/s13258-026-01737-z","relation":{},"ISSN":["1976-9571","2092-9293"],"issn-type":[{"value":"1976-9571","type":"print"},{"value":"2092-9293","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,27]]},"assertion":[{"value":"7 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Each individual patient supplied written confirmation of informed consent, and the protocol obtained approval from the ethical committee of The First Affiliated Hospital of Nanjing Medical University.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval and consent to participate"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}]}}